DescriptorName: ProstaticNeoplasms... Genetic and Epidemiology of Colorectal Cancer Consortium (GECCO), and the ProstateCancer Association Group to Investigate Cancer Associated Alterations in the Genome ... and the MR-Base platform).Participants 70 563 cases of cancer (22 898 prostatecancer, 15 748 breast cancer, 12 537 lung cancer, 11 488 ...
... specific antigen (PSA) has led to an early detection of prostatecancer (PCa) and a reduction of metastatic disease at diagnosis, PSA ... In men with previous negative pathological findings, ProstateCancer Antigen 3 and ConfirmMDx predicted the outcome of subsequent biopsy ... the efficacy and cost utility of these new technologies AbstractText: Prostatecancer is a heterogeneous disease with a wide variability.
Oncology (5) Prostatic Neoplasms (5), Neoplasms (2), more mentions
AbstractText: Androgen receptor-signaling inhibitor (ARSi) drugs prolong life in metastatic castration-resistant prostatecancer (mCRPC), but such tumors eventually become resistant and progress... Image-directed biopsy determined the presence or absence of prostatecancer at positive imaging sites AbstractText: PET/CT imaging was performed with [18F]-FDHT and [18F ...
Oncology (4) Prostatic Neoplasms (3), Neoplasms (2), more mentions
... present study investigates whether intake of these compounds may influence prostatecancer risk in human populations... median follow up of 11.5 years, 2,598 cases of prostatecancer (including 287 advanced cases) have been identified among 27,004 ... intervals (CI) for dietary isoflavones and coumestrol in relation to prostatecancer risk.
... incidence were found AbstractText: For patients with GS ≥7 receiving SRT, clinicians should weigh FFBF benefits of WPRT and ADT against toxicities. Future studies should explore the impact of WPRT on quality of life, clinical progression, and overall survival AbstractText: We evaluated patients with prostatecancer treated with radiation after surgery to remove the prostate... Keyword: Prostatecancer. Keyword: Prostatectomy.
Oncology (4) Prostatic Neoplasms (3), Neoplasms (1), more mentions
... standard of care in fit men with metastatic castration-naive prostatecancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE ... on the efficacy of treatments used for metastatic castration-resistant prostatecancer (mCRPC) in men treated upfront with ADT plus docetaxel for ... treated upfront with chemo-hormonal therapy for metastatic castration-naive prostatecancer.
AbstractText: Genomic aberrations have been identified in metastatic castration-resistant prostatecancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known AbstractText: In a prospective clinical trial, mCRPC patients underwent whole exome sequencing (n = 82) and RNA-sequencing ... Keyword: Castrate-resistance prostatecancer.
Abstract: Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostatecancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard ...
AbstractText: Moderately hypofractionated intensity modulated radiation therapy (HIMRT) for prostatecancer shortens the treatment course while providing outcomes comparable with those ... level data from a randomized trial AbstractText: Men with localized prostatecancer were randomized to CIMRT (75.6 Gy in 42 fractions over ... AbstractText: HIMRT is more cost-efficient than CIMRT for treating prostatecancer, even when taking into account the costs related to late ...
... ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing.
... use of [(18)F]- and [(68)Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostatecancer is now widespread... is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostatecancer.